Abivax to Current Three Abstracts for Obefazimod in Ulcerative Colitis on the UEG Week 2024
- Professor Bruce E. Sands, MD to current oral presentation of Part 2b, open-label, upkeep efficacy and security information at weeks 48 and 96 amongst week 8 induction non-responders in obefazimod-treated sufferers with reasonably to severely energetic ulcerative colitis (UC)
- Two moderated poster shows highlighting corticosteroid-free efficacy and security information of obefazimod at weeks 48 and 96 of an open-label upkeep trial, in addition to the influence of obefazimod induction remedy on mixed histologic and endoscopic outcomes at week 8 in sufferers with UC
PARIS, France, September 26, 2024 “ 08:30 a.m. CEST “ Abivax SA (Euronext Paris: FR0012333284 “ ABVX; NASDAQ: ABVX) (Abivax or the Firm), a clinical-stage biotechnology firm centered on creating therapeutics that harness the physique’s pure regulatory mechanisms to stabilize the immune response in sufferers with continual inflammatory illnesses, right this moment introduced that three scientific abstracts on its lead drug candidate, obefazimod, will probably be introduced in the course of the United European Gastroenterology (UEG) Week assembly, Oct. 12-15, 2024, in Vienna, Austria.
We look ahead to returning to UEGW to share new evaluation of our Part 2b trial information on obefazimod in sufferers with reasonably to severely energetic ulcerative colitis, stated Abivax Chief Medical Officer Fabio Cataldi, MD. With this presentation, we have now noticed further proof that obefazimod has the potential to advance the remedy paradigm, designed to be a once-daily oral remedy, for individuals residing with ulcerative colitis.
For extra info on the Abivax medical program and firm updates, please see the convention program on the UEG web site.
Obefazimod information to be introduced:
Presentation Title | Session | Presenter | Summary/Poster Quantity | Date/Time of Presentation |
Oral Presentation | ||||
Efficacy and security of obefazimod in UC sufferers at week 48 of an open-label upkeep research amongst medical non-responders at week 8 of the Part 2b induction trial | IBD New horizons in medical remedy – Half 2 | Prof. Bruce E. Sands, M.D., M.S.
Dr. Burrill B. Crohn Professor of Medication and Chief, Dr. Henry D. Janowitz Division of Gastroenterology, Icahn College of Medication at Mount Sinai, NY |
Tuesday, Oct. 15, 2024, from 11:30 AM to 12:30 PM CEST | |
Moderated Poster Shows | ||||
Corticosteroid-free efficacy and security of UC sufferers receiving once-daily obefazimod in an open label 96-week upkeep research amongst sufferers who have been receiving concomitant corticosteroids at induction baseline | Small molecules within the remedy of IBD | Prof. Séverine Vermeire, MD, PhD. Head of the IBD Heart on the College Hospitals Leuven, Belgium, and principal investigator in Europe for the research applications performed and ongoing with obefazimod in UC |
Tuesday, Oct. 15, 2024, from 14:30 PM to fifteen:30 PM CEST | |
Influence of obefazimod induction remedy on histologic and mixed histologic and endoscopic outcomes in sufferers with reasonably to severely energetic ulcerative colitis: week 8 outcomes from the Part 2b induction trial |
Small molecules within the remedy of IBD | Prof. Britta Siegmund, MD, PhD
Medical Director, Division of Gastroenterology, Infectiology and Rheumatology, Universitätsmedizin Berlin‹ |
Tuesday, Oct. 15, 2024, from 14:30 PM to fifteen:30 PM CEST |
About Obefazimod
Obefazimod, Abivax’s lead investigational drug candidate, is an orally administered small molecule that was demonstrated to probably improve the expression of a single microRNA, miR-124. Part 2 medical trials in sufferers with UC have generated constructive information, ensuing within the initiation of a pivotal international Part 3 medical trial program (ABTECT Program), with first sufferers enrolled in the US in October 2022. Initiation of a Part 2b medical trial in Crohn’s illness is predicted in Q3 2024, and exploration of potential mixture remedy alternatives in UC is ongoing.
About Abivax
Abivax is a clinical-stage biotechnology firm centered on creating therapeutics that harness the physique’s pure regulatory mechanisms to stabilize the immune response in sufferers with continual inflammatory illnesses. Based mostly in France and the US, Abivax’s lead drug candidate, obefazimod (ABX464), is in Part 3 medical trials for the remedy of reasonably to severely energetic ulcerative colitis. Extra info on the Firm is accessible at www.abivax.com. Observe us on LinkedIn and X, previously Twitter, @ABIVAX.
Contact:
Patrick Malloy
SVP, Investor Relations Abivax SA
[email protected]
+1 847 987 4878
FORWARD-LOOKING STATEMENTS
This press launch comprises forward-looking statements, forecasts and estimates, together with these referring to the Firm’s enterprise and monetary goals. Phrases reminiscent of count on, ahead, will and variations of such phrases and comparable expressions are meant to establish forward-looking statements. These forward-looking statements embrace statements regarding or implying the therapeutic potential of Abivax’s drug candidates, in addition to the timing of initiation of a Part 2b medical trial of obefazimod in Crohn’s illness. Though Abivax’s administration believes that the expectations mirrored in such forward-looking statements are cheap, traders are cautioned that forward-looking info and statements are topic to numerous dangers, contingencies and uncertainties, a lot of that are troublesome to foretell and customarily past the management of Abivax, that might trigger precise outcomes and developments to vary materially from these expressed in, or implied or projected by, the forward-looking info and statements. An outline of those dangers, contingencies and uncertainties might be discovered within the paperwork filed by the Firm with the French Autorité des Marchés Financiers pursuant to its authorized obligations together with its common registration doc (Doc d’Enregistrement Universel) and in our Annual Report on Type 20-F filed with the U.S. Securities and Change Fee on April 5, 2024 underneath the caption Threat Elements. These dangers, contingencies and uncertainties embrace amongst different issues, the uncertainties inherent in analysis and improvement, future medical information and evaluation, choices by regulatory authorities, such because the FDA or the EMA, relating to whether or not and when to approve any drug candidate, in addition to their choices relating to labelling and different issues that might have an effect on the supply or business potential of such product candidates. Particular consideration must be given to the potential hurdles of medical and pharmaceutical improvement together with additional evaluation by the corporate and regulatory companies and IRBs/ethics committees following the evaluation of preclinical, pharmacokinetic, carcinogenicity, toxicity, CMC and medical information. Moreover, these forward-looking statements, forecasts and estimates are solely as of the date of this press launch. Readers are cautioned to not place undue reliance on these forward-looking statements. Abivax disclaims any obligation to replace these forward-looking statements, forecasts or estimates to replicate any subsequent adjustments that the Firm turns into conscious of, besides as required by legislation. Details about pharmaceutical merchandise (together with merchandise presently in improvement) which is included on this press launch shouldn’t be meant to represent an commercial. This press launch is for info functions solely, and the knowledge contained herein doesn’t represent both a proposal to promote, or the solicitation of a proposal to buy or subscribe securities of the Firm in any jurisdiction. Equally, it doesn’t give and shouldn’t be handled as giving funding recommendation. It has no reference to the funding goals, monetary state of affairs or particular wants of any recipient. It shouldn’t be regarded by recipients as an alternative to train of their very own judgment. All opinions expressed herein are topic to alter with out discover. The distribution of this doc could also be restricted by legislation in sure jurisdictions. Individuals into whose possession this doc comes are required to tell themselves about and to look at any such restrictions.
Supply: Abivax